DBC-664

DBC-664 is a bispecific T-cell engager antibody from Duboce Biopharmaceuticals, with TCG Labs Soleil as partner. A T-cell engager that binds ALPP or ALPPL2 on cancer cells and CD3 on T cells, aimed at antigens that are highly expressed, most evenly in ovarian and endometrial cancers. Its furthest stage is phase 1, for ovarian adenocarcinoma, endometrial adenocarcinoma, malignant germ cell tumours and lung adenocarcinoma. ClinicalTrials.gov registers it in one study linked below. Phase 1a/1b NCT07705035 recruiting; started 17 July 2026. Whether it works in people has not been established unless a trial below reports it.